Drug Discovery World

JUNE 14, 2023

We are a cell therapy company that uses a very specific receptor to engineer T cells and administer these engineered T cells back to solid tumour patients. We have now our lead product in a Phase I/II study, which is a HER-2 directed tag T cell product for patients with HER-2 positive solid tumours.

Research 52

Research Engineer In-Vivo Production 52

pharmaphorum

AUGUST 25, 2022

The double-headed antibody binds to CD3 on T cells and redirects them to BCMA-expressing myeloma cells, with the aim of stimulating an immune attack on the tumour, which remains incurable despite a slew of new therapies reaching the market in recent years.

Antibody 98

Antibody Marketing Drugs Medicine 98

pharmaphorum

JANUARY 5, 2021

Like PD-L1, TIGIT is thought to act as a molecular brake that stops T cells from attacking tumours, and tiragolumab is currently leading the pack among drugs targeting the immune checkpoint. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

pharmaphorum

APRIL 27, 2022

It was the first time ever that a HER2-directed therapy has shown a benefit in patients with HER2-low breast cancer, a group which accounts for around 55% of all cases of the disease versus 25% for HER2-positive tumours. The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on. billion. .”

Sales 57

Sales Drugs Antibody Licensing 57

pharmaphorum

APRIL 5, 2022

It’s the first treatment for mUM in the EU, as well as the first BiTE drug to treat a solid tumour. The therapy is a bispecific T cell engager (BiTE) molecule, consisting of a soluble TCR targeting gp100 expressed on cancer cells fused to a protein that binds CD3 receptors on lymphocytes.

Protein 52

Protein Sales Drugs Trials 52

pharmaphorum

OCTOBER 29, 2021

Merck is the obvious partner for that ambition as Keytruda is in the ascendency among checkpoint inhibitors for TNBC, having also recently also picked up an FDA approval pre-surgery alongside chemotherapy in the neoadjuvant setting, as well as in the post-surgery (adjuvant) setting as a monotherapy, to prevent tumours from recurring.

Trials 52

Trials Sales FDA Approval Production 52

pharmaphorum

DECEMBER 23, 2022

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. The animal results showed dose-dependent tumour growth inhibition and efficacy beyond the treatment window, despite clearance of drug from blood and tissues.

Development 52

Development Drugs Clinical Development Antibody 52

Drug Discovery World

APRIL 17, 2023

Totus uses molecular tags that track drug binding in individual cells to screen billions of drug molecules across thousands of genes in parallel, combined with machine learning techniques. The post First patient dosed with PI3Kα inhibitor for solid tumours appeared first on Drug Discovery World (DDW).

Clinical Trials 52

Clinical Trials Clinical Trials Trials Medicine 52

Drug Discovery World

NOVEMBER 9, 2023

Damian Trojanowski, Dr, R&D Specialist, Antibody Discovery Group, Pure Biologics, on: ‘Anti-GARP/TGFb1 antibodies in new twist – multifunctional shapers of anti-tumour immunity’. Jonathan Fisher, PhD, Group Leader, University College London, on: ‘Local secretion of immune active proteins for direct and bystander tumour killing’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

OCTOBER 28, 2022

Radioactive implant ‘completely eliminated’ tumours . Click’ chemistry used to tag proteins made by cancer cells . Could mRNA become a ‘universal’ Covid-19 treatment? . New research suggests messenger RNA can be effectively used as a ‘universal’ therapy against different coronaviruses. .

Drugs 52

Drugs Antibody Protein RNA 52

Drug Discovery World

NOVEMBER 13, 2023

De Luca will present on Tripkin, a best-in-class potential for tumour-targeted interleukin-2 (IL2) potentiated by tumour necrosis facor (TNF). Stefan Warmuth, PhD, Vice President, Head CMC, Numab Therapeutics, on: ‘Update on Numab’s affinity-balanced PD-L1x4-1BBxHSA trispecific tumour-targeted immunotherapy’.

Protein 59

Protein Antibody Engineer Scientist 59

pharmaphorum

OCTOBER 4, 2022

The Biobank was launched in 2020, with an initial aim of enrolling at least 1,000 patients with locally advanced or metastatic solid tumours and haematologic malignancies undergoing standard of care therapy. Participants can also receive tumour biomarker testing that may help offer them different treatment options.

Biobanking 104

Biobanking Clinical Trials Clinical Trials Trials 104

Delveinsight

DECEMBER 3, 2020

It has been speculated that modifications to the epigenome drive cell ageing, especially a process known as DNA methylation, by which methyl groups are tagged onto DNA. Merck first collaborated with the biotech in a pact worth nearly USD 700 million two years ago, with an aim on a series of solid tumour targets.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Drug Discovery World

OCTOBER 21, 2022

The main principle involves a well-defined light source such as that produced by lasers that excites fluorescent tags bound to the cells or particles present in a sample. A major breakthrough in the technology was the development of biologically active fluorescent reagents that could be detected by the instruments.

Reagent 52

Reagent Antibody Drugs Protein 52